移植物抗宿主病 (GvHD):亞太地區的流行病學的預測 (到2028年)

亞太地區的主要5個國家 (澳洲、中國、印度、日本、韓國) 的移植物抗宿主病 (GvHD)的發病數量，2018年∼2028年之間預計從8,794件到13,673件，以年度平均 (AGR) 5.55％的速度增加。這個增加，原因之一是這5個國家的移植手術有緩慢地上升趨勢。預計還有aGvHD的發病數量從2018年的4,650案例，到2028年增加到7,212案例，cGvHD的發病數量從2018年的4,144案例，到2028年增加到6,461案例。

本報告提供亞太地區的主要5個國家 (澳洲、中國、印度、日本、韓國) 的移植物抗宿主病 (GvHD)的發病情形與今後預測相關分析，疾病的特徵和目前的發病情形，今後10年的發病數量、患病數量的預測值等調查。

第1章 目錄

第2章 移植物抗宿主病 (GvHD):摘要整理

第3章 流行病學

• 病的背景
• 風險要素與並存症
• 全球市場的過去趨勢
  • 澳洲
  • 中國
  • 印度
  • 日本
  • 韓國
• 預測手法
  • 使用的資訊來源
  • 不使用的資訊來源
  • 預測的前提條件與方法
• GvHD的流行病學預測 (2018∼2028年)
  • 最初的同類HSCT (造血幹細胞移植)的實施數量3年的患病人數
  • 最初的同類HSCT的aGvHD (急性GvHD)的發病數量
  • 最初的同類HSCT的cGvHD (慢性GvHD)的發病數量討論
  • aGvHD、cGvHD的發病數量:各年齡
  • aGvHD、cGvHD的發病數量:各等級
  • aGvHD、cGvHD的發病數量:各重症度
  • aGvHD已診斷的發病數量:100天的死亡率
  • cGvHD的發病數量:1年的死亡率
  • aGvHD的3年的患病人數
  • cGvHD的3年的患病人數
• 討論
  • 流行病學的預測相關考察
  • 分析的限制
  • 分析的優勢

第4章 附錄

GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.

GlobalData epidemiologists utilized historical HSCT data available through country-wide registry reports in the 5GM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, GlobalData epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.

The following data describes epidemiology of GvHD cases. In 2018, the 5GM had 8,794 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 13,673 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 5.55%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 5GM. In the 5GM, the diagnosed incident cases of aGvHD will increase from 4,650 cases in 2018 to 7,212 cases in 2028, at an Annual Growth Rate (AGR) of 5.51% per year, and the diagnosed incident cases of cGvHD will increase from 4,144 cases in 2018 to 6,461 cases in 2028, at an AGR of 5.59% per year.

Scope

• Graft Versus Host Disease (GvHD) Asia Pacific Epidemiology Report provides an overview of the risk factors and global trends of GvHD in the five growth markets (5GM: Australia, China, India, Japan, and South Korea).
• This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 5GM: diagnosed incident cases of first allogeneic Hematopoietic stem cell transplantation (HSCT), acute GvHD (aGvHD), and chronic GvHD (cGvHD); diagnosed three-year prevalent cases of aGvHD and cGvHD; and diagnosed incident cases of aGvHD and cGvHD by grade and severity respectively. Additionally, 100-day mortality in aGvHD and one-year mortality cases in cGvHD is also included in this report.
• The GvHD Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

Reasons to Buy

The GvHD Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global GvHD market.
• Quantify patient populations in the global GvHD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the aGvHD grades and cGvHD severity stages that present the best opportunities for GvHD therapeutics in each of the markets covered.
• Understand magnitude GvHD market by mortality rates and three-year prevalent cases.

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Graft-Versus-Host Disease: Executive Summary

• 2.1 Related Reports
• 2.2 Upcoming Reports

3 Epidemiology

• 3.1 Disease Background
• 3.2 Risk Factors and Comorbidities
• 3.3 Global and Historical Trends
• 3.3.1 Australia
• 3.3.2 China
• 3.3.3 India
• 3.3.4 Japan
• 3.3.5 South Korea
• 3.4 Forecast Methodology
• 3.4.1 Sources Used
• 3.4.2 Sources Not Used
• 3.4.3 Forecast Assumptions and Methods
• 3.5 Epidemiological Forecast for GvHD (2018-2028)
• 3.5.1 Incident Cases of First Allogeneic HSCT
• 3.5.2 Incident Cases of aGvHD in First Allogeneic HSCT
• 3.5.3 Incident Cases of cGvHD in First Allogeneic HSCT
• 3.5.4 Age-Specific Incident Cases of aGvHD and cGvHD
• 3.5.5 Diagnosed Incident Cases of aGvHD by Grade
• 3.5.6 Diagnosed Incident Cases of cGvHD by Severity
• 3.5.7 100-Day Mortality in Diagnosed Incident Cases of aGvHD
• 3.5.8 One-Year Mortality in Diagnosed Incident Cases of cGvHD
• 3.5.9 Three-Year Diagnosed Prevalent Cases of aGvHD
• 3.5.10 Three-Year Diagnosed Prevalent Cases of cGvHD
• 3.6 Discussion
• 3.6.1 Epidemiological Forecast Insight
• 3.6.2 Limitations of Analysis
• 3.6.3 Strengths of Analysis

4 Appendix

• 4.1 Bibliography
• 4.2 About the Authors
• 4.2.1 Epidemiologist
• 4.2.2 Reviewers
• 4.2.3 Global Director of Therapy Analysis and Epidemiology
• 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
• 4.3 About GlobalData
• 4.4 Contact Us
• 4.5 Disclaimer

List of Tables

• Table 1: Risk Factors for GvHD

List of Figures

• Figure 1: 5GM, Diagnosed Incident Cases of GvHD in Diagnosed Incident Cases of First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018 and 2028
• Figure 2: 5GM, Diagnosed Incidence of aGvHD per 100 First Allogeneic HSCT Cases, All Ages, Both